GenoMethods applies ethical standards to news, analysis, explainers, rankings, reviews, company coverage and other editorial work.
These principles are intended to support reliable biotechnology publishing by clarifying how independence, evidence, sourcing and accountability should influence editorial judgment.
Our Ethical Principles
- Independence. Advertising, access and commercial relationships do not determine independent editorial conclusions. Editors should not promise positive coverage, favorable rankings or suppression of accurate reporting in exchange for payment or benefit.
- Accuracy. Material facts should be checked against reliable sources, and headlines should reflect the evidence without overstating certainty. Accuracy includes describing the stage and limitations of evidence, not only reproducing correct numbers.
- Fairness. Sources should not be quoted or summarized in ways that materially change their intended meaning. Relevant context should be included for serious disputed claims. Fairness does not require treating unsupported claims as equivalent to well-supported evidence.
- Transparency. Readers should be able to distinguish facts, analysis, company claims, expert interpretation and commercial material. Where important uncertainty exists, the language should not conceal that uncertainty.
- Conflicts of interest. Editors and contributors should disclose relevant financial, professional, commercial or personal interests that could reasonably affect their work.
- Responsible sourcing. Named and primary sources are preferred. Unnamed sources are used rarely and under editorial controls because anonymity reduces the information readers can use to evaluate a source directly.
- Sensitive subjects. Health, safety, legal, financial and reputational claims require additional care because unsupported certainty can have more significant consequences.
- Accountability. Verified factual errors may be corrected, clarified or updated. Editorial independence includes responsibility for correcting the record when evidence shows that published information is materially wrong.
Scientific and Clinical Responsibility
Biotechnology coverage should preserve distinctions that materially affect how readers understand evidence. GenoMethods therefore aims to distinguish:
- computational prediction from experimental validation;
- preclinical findings from human evidence;
- early activity from established clinical benefit;
- regulatory designation from approval;
- scientific feasibility from commercial success.
These distinctions reduce the risk that preliminary findings are presented as more mature or conclusive than the available evidence supports.
We Avoid
- guaranteed medical or financial outcomes;
- unsupported safety or efficacy claims;
- personalized diagnosis or treatment instructions;
- personalized legal or investment advice;
- fear-based claims unsupported by evidence;
- fake reviews or testimonials;
- commercial material intentionally disguised as independent editorial work.
Advertising, Rankings and Commercial Activity
GenoMethods currently displays third-party advertising through Google AdSense. Sponsored articles and paid press releases are not currently part of the standard publishing model.
Commercial activity does not provide the right to change independent editorial conclusions, control corrections or purchase favorable evaluations.
Paid visibility does not determine editorial ranking position.
Images, Data and AI
Images, charts and data visualizations should not materially mislead readers. A visual representation should not imply evidence, precision or events that the underlying material does not support.
AI-assisted tools are used only to create, prepare or edit images and other visual materials. AI is not used for article writing, drafting, rewriting, summarization, research, fact-checking, source monitoring, translation, metadata, descriptions, tagging, categorization, biographies or other editorial text.
Human editors remain responsible for sourcing, verification and publication decisions.
Privacy and Unnecessary Harm
Sensitive personal information should not be included merely because it is available if it has no meaningful relevance to the story. Relevance and public-interest value should guide whether personal details are necessary to explain the subject.
Corrections and Reader Accountability
Readers are encouraged to identify possible errors, missing context or relevant evidence that could materially affect an article. Useful feedback should identify the specific issue and supporting information where available.
Corrections: corrections@genomethods.org
Related Pages
1 Broadway
Cambridge, MA 02142
United States